Interestingly, although the inhibitory effect of ICS II on PDE5 activity is just half of SIL (Dell'agli et al., 2008), it effectively inhibits melanoma according to recent reports (Wu et al., 2013; Wu et al., 2015). Here, PDE5A is linked to melanoma.